Clinical Scorecard: Reevaluating Immunotherapy in Colorectal Cancer Liver Metastases: The Role of the Hepatic Metastatic Microenvironment Beyond Mismatch Repair

At a Glance

Key Highlights

• dMMR/MSI-H status is the primary biomarker for immunotherapy in colorectal cancer.
• Active liver disease may limit the efficacy of checkpoint inhibitors.
• Clinical outcomes vary significantly based on hepatic involvement.
• Retrospective analyses indicate poorer responses in patients with active liver metastases.
• The hepatic environment can alter immune cell function and treatment response.

Guideline-Based Recommendations

Diagnosis

• Assess MMR/MSI status for immunotherapy eligibility.

Management

• Consider the impact of active liver disease on treatment decisions.

Monitoring & Follow-up

• Evaluate disease burden and liver status during treatment.

Risks

• Active liver metastases may predict poorer outcomes with immunotherapy.

Patient & Prescribing Data

Patients with metastatic colorectal cancer, both dMMR/MSI-H and pMMR/MSS.

Checkpoint inhibitors are not standard for unselected pMMR/MSS disease.

Clinical Best Practices

• Incorporate liver disease status into treatment planning.
• Monitor for variations in response based on hepatic involvement.
• Utilize a multidisciplinary approach to manage complex cases.

Related Resources & Content

• KEYNOTE-177 Study
• CheckMate 8HW Study
• Pakvisal et al. Study